CEO Granted 84,500 Shares, Resulting in 15% Dilution and 75% Voting Control
UPC sits 34% above its 52-week low of $2.
Summary
Universe Pharmaceuticals INC granted 84,500 shares to its CEO, resulting in approximately 15% dilution and increasing the CEO's voting control to 75%.
Key Events · Financing and Capital Events · UPC
-
Significant Share Grant to CEO
CEO Gang Lai received an aggregate of 84,500 Class A and Class B ordinary shares on May 7, 2026, as compensation for past services.
-
Material Dilution
The issuance of 84,500 shares represents approximately 15% dilution to existing shareholders, based on the company's pre-grant outstanding shares.
-
Increased CEO Voting Control
Following this issuance, Mr. Lai and his holding company beneficially own approximately 75.0% of the company's total voting power.
-
Execution of Equity Incentive Plan
This grant was made under the 2026 Equity Incentive Plan, which was adopted on April 14, 2026, and initially authorized 84,500 shares.
Analysis · UPC · Life Sciences
The company issued 84,500 shares to its CEO, Mr. Gang Lai, as compensation for past services. This grant represents a significant dilution of approximately 15% for existing shareholders. Following this issuance, the CEO's beneficial ownership increases to approximately 75% of the company's total voting power, consolidating control.
At the time of this filing, UPC was trading at $2.68 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $2.00 to $11.00. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.